Sökning: onr:"swepub:oai:DiVA.org:uu-400759" > CAIX-targeting radi...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 04948naa a2200457 4500 | |
001 | oai:DiVA.org:uu-400759 | |
003 | SwePub | |
008 | 200103s2019 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4007592 URI |
024 | 7 | a https://doi.org/10.1038/s41598-019-54824-52 DOI |
040 | a (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Huizing, Fokko J.u Radboud Univ Nijmegen, Med Ctr, Dept Radiat Oncol, Nijmegen, Netherlands4 aut |
245 | 1 0 | a CAIX-targeting radiotracers for hypoxia imaging in head and neck cancer models |
264 | c 2019-12-11 | |
264 | 1 | b Springer Science and Business Media LLC,c 2019 |
338 | a electronic2 rdacarrier | |
520 | a Hypoxia-induced carbonic anhydrase IX (CAIX) expression is a prognostic marker in solid tumors. In recent years many radiotracers have been developed, but a fair comparison of these compounds is not possible because of the diversity in tumor models and other experimental parameters. In this study we performed a direct in vivo comparison of three promising CAIX targeting radiotracers in xenografted head and neck cancer models. The biodistribution of [In-111]In-DOTA-ZCAIX:2 was directly compared with [In-111]In-DTPA-G250-F(ab')(2) and [In-111] In-DTPA-G250 in female BALB/C nu/nu mice bearing two HNSCC xenografts with different levels of CAIX expression. In vivo biodistribution was quantified by means of microSPECT/CT scans and ex vivo biodistribution was determined with the use of gamma-counter. Tumors were snap frozen and sections were stained for CAIX expression, vessels, hypoxia (pimonidazole) and tumor blood perfusion. Tracer uptake was significantly higher in SSCNij153 tumors compared to SCCNij185 tumors for [In-111]In-DOTA-HE3-ZCAIX:2: 0.32 +/- 0.03 versus 0.18 +/- 0.01%ID/g,(p = 0.003) 4 h p.i., for [In-111]In-DTPA-girentuximab-F(ab')(2): 3.0 +/- 0.5%ID/g and 1.2 +/- 0.1%ID/g (p = 0.03), 24 h p.i. and for [In-111]In-DTPA-girentuximab: 30 +/- 2.1%ID/g and 7.0 +/- 1.0%ID/g (p = 0.0002) 72 h p.i. SPECT imaging with both [In-111]In-DTPA-girentuximab-F(ab') 2 and [111In]In-DTPA-girentuximab showed a clear difference in tracer distribution between the two tumor models. The whole IgG, i.e. [In-111]In-DTPA-girentuximab, showed the highest tumor-to-muscle ratio. We showed that different CAIX-targeting radiotracers can discriminate a low CAIX-expressing tumor from a high CAIX-expressing head and neck cancer xenografts model. In these hypoxic head and neck xenograft models [In-111]In-DTPA-girentuximab showed the most promising results. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Radiologi och bildbehandling0 (SwePub)302082 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Radiology, Nuclear Medicine and Medical Imaging0 (SwePub)302082 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
700 | 1 | a Garousi, Javadu Uppsala universitet,Medicinsk strålningsvetenskap4 aut0 (Swepub:uu)javga723 |
700 | 1 | a Lok, Jasperu Radboud Univ Nijmegen, Med Ctr, Dept Radiat Oncol, Nijmegen, Netherlands4 aut |
700 | 1 | a Franssen, Gerbenu Radboud Univ Nijmegen, Med Ctr, Dept Radiol, Nijmegen, Netherlands;Radboud Univ Nijmegen, Med Ctr, Dept Nucl Med, Nijmegen, Netherlands4 aut |
700 | 1 | a Hoeben, Bianca A. W.u Radboud Univ Nijmegen, Med Ctr, Dept Radiat Oncol, Nijmegen, Netherlands4 aut |
700 | 1 | a Frejd, Fredrik Y.u Uppsala universitet,Medicinsk strålningsvetenskap,Affibody AB, Solna, Sweden4 aut0 (Swepub:uu)freni195 |
700 | 1 | a Boerman, Otto C.u Radboud Univ Nijmegen, Med Ctr, Dept Radiol, Nijmegen, Netherlands;Radboud Univ Nijmegen, Med Ctr, Dept Nucl Med, Nijmegen, Netherlands4 aut |
700 | 1 | a Bussink, Johanu Radboud Univ Nijmegen, Med Ctr, Dept Radiat Oncol, Nijmegen, Netherlands4 aut |
700 | 1 | a Tolmachev, Vladimiru Uppsala universitet,Medicinsk strålningsvetenskap4 aut0 (Swepub:uu)vladtolm |
700 | 1 | a Heskamp, Sandrau Radboud Univ Nijmegen, Med Ctr, Dept Radiol, Nijmegen, Netherlands;Radboud Univ Nijmegen, Med Ctr, Dept Nucl Med, Nijmegen, Netherlands4 aut |
710 | 2 | a Radboud Univ Nijmegen, Med Ctr, Dept Radiat Oncol, Nijmegen, Netherlandsb Medicinsk strålningsvetenskap4 org |
773 | 0 | t Scientific Reportsd : Springer Science and Business Media LLCg 9q 9x 2045-2322 |
856 | 4 | u https://doi.org/10.1038/s41598-019-54824-5y Fulltext |
856 | 4 | u https://uu.diva-portal.org/smash/get/diva2:1382508/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print |
856 | 4 | u https://www.nature.com/articles/s41598-019-54824-5.pdf |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-400759 |
856 | 4 8 | u https://doi.org/10.1038/s41598-019-54824-5 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy